




To systematically review erectile function (EF) outcomes following primary 
whole gland (WG) and focal ablative therapies for localized prostate cancer 
(LPC) to ascertain whether the treatment modality or intended treatment 
volume affects the time taken to recover baseline EF. 
 
Method and materials: 
A systematic review was performed according to the preferred reporting items 
for systematic review and meta-analysis (PRISMA) statement. Inclusion 
criteria were men with LPC treated with primary, ablative therapy. Primary 
outcome was the return to baseline EF measured with objective, validated 
symptoms scores.  Secondary outcome was use of phosphodiesterase 
inhibitors or erectile aids.  Meta-analysis was not performed owing to 
heterogenous outcome measures.   
 
Results: 
Of 222 articles identified in February 2017, 55 studies which reported EF after 
ablative therapy were identified but only 17 used validated outcome measures 
and met inclusion criteria. WG cryotherapy was utilized in two studies, WG 
HIFU in five, focal cryotherapy in two, focal HIFU in three, focal phototherapy 
or laser therapy in four, vascular targeted photodynamic therapy (VTP) in 
three and irreversible electroporation in two.  WG cryotherapy was associated 
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with a significant decline in EF at 6 months with minimal improvement at 36 
months.  Baseline IIEF-15 of patients undergoing focal HIFU fell 30 points at 
one month but returned to baseline by six months. The remaining focal 
therapies demonstrated minimal or no effect on EF but the men in these 
studies had small foci of disease.  The review is limited by lack of randomized 
studies and heterogenous outcome measures. 
 
Conclusions 
Most studies assessing the outcomes of focal therapy on sexual function were 
not of high quality, used heterogenous outcomes and had relatively short 
follow up, highlighting the need for more robustly designed studies utilizing 
validated PROMS for comparison. However, FT in general resulted in less 





Quality of life outcomes including maintaining EF are major factors in the 
decision to proceed with intervention in men with LPC1.   Radical 
prostatectomy (RP), radiotherapy and active monitoring for LPC are 
associated with equivalent survival at 10 years2. Moreover, 17% of men in the 
ProtecT trial had erections sufficient for intercourse following RP compared 
with 30% of those on active monitoring3. EF was reported with expanded 
prostate cancer index composite (EPIC) scores unlike in most other LPC 
radical therapy trials where validated questionnaires have not been used 
routinely.  Ablative therapy (whole gland (WG) or focal) was introduced with 
the hope of avoiding some of the adverse effects of radical therapy including 
erectile dysfunction (ED), bladder or bowel dysfunction and urinary 
incontinence as well as avoiding the psychological burden of active 
monitoring.  Ablative therapies for prostate cancer are now available in many 
European countries as well as Canada and the USA where HIFU was first 
approved by the FDA in 20154. 
 
Prostate cancer was initially believed to be a multifocal disease1.  However, 
histological studies have demonstrated single foci or significant disease in just 
one half of the prostate1.   More recently, whole genome sequencing of areas 
of prostate cancer and normal prostate tissue within single prostate glands 
have shown common mutations within the cancer and in the normal tissue 
suggesting there is a ‘field effect’ occurring within the whole gland5.  It should 
be clear that a field-effect is not necessarily indicative that new aggressive 
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tumours will develop in untreated tissue as evidenced by the safe 
management of patients with active surveillance2. 
 
Alongside improving imaging and biopsy techniques including MRI fusion, 
novel understanding of the pathology initiated focal therapy (FT).  Ablative 
energy sources include cryotherapy, HIFU, laser or photodynamic therapy 
(PT) and Irreversible electroporation (IRE). Cryotherapy was one of the first 
ablative techniques to be introduced6.  It induces cell lysis by cooling tissues 
to –40°C7.  Autonomic dysfunction occurs if the nearby neurovascular tissues 
are cooled to 3°C which may be irreversible at -20°C which accounts for the 
high rates of ED observed after WG cryotherapy.   HIFU focuses ultrasound 
energy leading to tissue ablation via thermal coagulation necrosis and 
acoustic cavitation8.  It has the potential of more precise ablation than 
cryotherapy but many men nevertheless report ED.   Photodynamic therapy 
induces cell death via cytotoxic oxidative stress. IRE uses pulses of direct 
current to create nanopores within the cell membrane leading to apoptosis9-11.   
 
There are no published randomized controlled trials (RCT) comparing 
oncological outcomes of radical therapy and FT for LPC. The PART study is 
currently in the pilot phase, randomizing men with intermediate risk disease to 
RP and FT12.  If ablative therapies are to be offered as viable alternatives to 
radical treatment and active monitoring, men must be informed of the precise 
risks of ED in an objective and understandable manner.  Currently, ED 
reporting after FT is not interpretable by patients as many studies within the 
existing literature either use their own definitions of ED or use no definition at 
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all13.   The change in pre-treatment EF, time taken to return to this baseline 
level and use of any support such as tablets, injections or erectile aids eg 
Vacuum Erectaid would be meaningful to patients but are not routinely 
reported.   
 
The effects on EF after ablative therapy have not been systematically 
reported and compared. This is particularly important for patient counseling as 
the incidence of decision regret in LPC is related to morbidity, particularly 
sexual morbidity and decision regret may be reduced by increased 
information and support prior to the decision14,15.  This study aims to 
determine and compare whether the modality and/or intended treatment 
volume of ablative therapy i.e. focal or WG might affect the severity of ED and 
return to baseline function. 
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2. Material and methods: 
2.1 Search strategy 
A systematic review of the Cochrane library, Scopus and Pubmed was 
performed from inception to February 2017 according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (‘PRISMA’) 
statement16.  Search terms included ‘erectile dysfunction’, ‘focal therapy’, 
‘ablation’, ‘HIFU’ and ‘cryotherapy’.  The full search for PubMed is shown in 
Appendix A.  No time limit for publications was applied.  The review was 
registered with PROSPERO (registration number 42016042070). 
 
2.2 Study eligibility 
Study eligibility was defined using the population, intervention, comparator, 
outcome and study design approach.  For inclusion, studies needed to include 
men with LPC treated with primary ablative therapy either as FT (intervention) 
or WG therapy (comparator)17. Studies needed to report validated EF 
outcomes such as the EPIC, the UCLA prostate cancer index (UCLAPCI), the 
prostate cancer quality of life survey, the 15 item international index of erectile 
function (IIEF-15) or the shortened 5 item international index of erectile 
function (IIEF-5) also known as the sexual health inventory for men (SHIM) 
score18-20.  
 
Included studies needed to contain five or more patients and report EF before 
ablative therapy with at least six months follow up.  Studies reporting scores 
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as ranges, duplicates, non-English language (if no translation available), 
reviews, case reports, letters and non-full text articles were excluded.  NFW, 
JN and TY independently reviewed eligibility and assessed bias at study level 
using Cochrane bias assessment tools.  Incongruities were resolved by 
consensus of all authors. 
 
2.3 Outcome measures 
The primary endpoint was the time to return to baseline of a validated EF 
outcome measure.  Secondary endpoint was the use of erectile aids and 
phospho-diesterase type 5 inhibitors (PDE5-I) following therapy.  
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3. Results 
3.1 Search results 
Of 222 studies initially identified on 2 February 2017, 17 studies met the 
inclusion criteria after removal of duplicates, non-English language, reviews, 
letters, case reports, non-human studies and non-full text articles (figure 1)21-
35.  Three papers were excluded after full text examination as WG and focal 
cryotherapy were amalgamated.  The included studies with together with bias 
assessment are shown in table 4.  
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3.2 Whole gland therapy 
WG cryotherapy was used in two of the included studies, the first of which 
was published in 2006 (figure 2 and table 1)30,31.  In Liu et al’s study, subjects 
initially had no ED (mean IIEF-5 23.0/25) but reported severe ED six months 
after therapy and showed no subsequent improvement after 24 months.  
Malcolm et al retrospectively investigated health related quality of life scores 
using the UCLAPCI in 81 patients treated with WG cryotherapy and compared 
the outcomes of patients undergoing brachytherapy, open and laparoscopic 
RP31.   They excluded patients with sexual function scores less than 30. Their 
patients showed a similar pattern of decline at six months, which did not 
improve over the three year study.   
 
WG HIFU was utilized in five studies (figure 3)22,25,28,30,34.  Liu et al found that 
the baseline IIEF-5 score of their 120 patients fell from 22.1 (no ED) to 
8.55/25 (moderate ED) at six months.  This rose slightly to 9.36 over 24 
months, still corresponsing to moderate ED.  Shoji et al followed 326 patients 
who underwent WG HIFU with neuro-vascular bundle (NVB) sparing34.  Their 
baseline IIEF-5 was only 6.3 representing severe ED and subjects did not see 
any positive change in IIEF scores following ablative therapy as would be 
expected given their very poor baseline function.  Li et al followed 55 patients 
in a non-randomized study comparing EF outcomes in WG HIFU and targeted 
cryotherapy using IIEF-15 EFD28. The baseline IIEF-15 EFD for WG HIFU 
patients was 27.3, which fell to 15.5 at six months but then steadily increased 
to 22.3 at 24 months, which was not significantly different to baseline.  The 
improvements continued to 36 months (table 2 and figure 3).  Patients were 
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younger (57.5 years) than in the Liu et al and Shoji et al studies. Patients in 
the Liu et al study also had higher presenting PSA (17.0 vs 7.5).  Li et al 
excluded patients over 65 and those with baseline IIEF-15 EFD less than 26 
out of 30.  The other key difference was that all patients received 50-100mg of 
Sildenafil three times weekly for the first month and then as needed; they 
were also encouraged to use a penile vacuum pump after the first month.  
 
In the first published UK series utilizing WG HIFU, Ahmed et al reported IIEF-
15 scores of 172 men at three monthly intervals up to 12 months22. Only 77 
and 34 of the 172 men given WG HIFU patients completed IIEF-15 scores at 
six and 12 months and so it is difficult to interpret the true change from 
baseline. Chin et al reported IIEF-15 EFD as part of a phase one trial into MRI 
guided trans-urethral ultrasound ablation (MRI-TULSA)25.  The ablation was 
described as ‘conservative whole gland’ giving lesions a 3mm margin.  
Baseline IIEF-15 EFD of 13 fell to seven at one month, and rose to 13 at 12 
months, which was not statistically different to baseline.  
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3.3 Focal therapy 
3.3.1 Focal cryotherapy 
The search identified two studies utilizing focal cryotherapy24,28.  Li et al 2010 
was the earliest FT paper.  Mean baseline IIEF-15 EFD of the 47 patients was 
27.8.  Following focal cryotherapy, IIEF-15 EFD fell to 9.8 at 6 months and 
steadily rose, such that the difference at 36 months was not statistically 
significant from baseline (figure 4).   
 
Barret et al study reported IIEF-5 scores at baseline and 12 months for 50 
patients who underwent focal cryotherapy (hemiablation).  Median IIEF-5 at 
baseline was 19 (IQR 9-25) and 14 (IQR 8-25) at 12 months. They did not 







3.3.2 Focal HIFU 
Focal HIFU was utilized in three studies21,24,35.  The first to be published was 
Ahmed et al in 2012, two years after the first focal cryotherapy paper21.  
 
Yap et al amalgamated 118 patients from three prospective, non-randomized, 
registered trials carried out between 2009 and 2013 (HEMI, FOCAL and 
LESION-control) including results from the Ahmed et al 2012 paper21,35-37. 
Figure 2 shows the total IIEF-15 of the FOCAL (n=42), HEMI (n=20) and 
LESION-CONTROL (n=56) trials.  Baseline age, PSA and Gleason scores 
were similar.  Patients in the FOCAL trial had lesions identified via MRI and 
template biopsy ablated with 3-5mm margins.  The HEMI trial treated the 
affected lobe with a 5mm section in the contra-lateral lobe.  The LESION-
CONTROL trial only ablated lesions of 0.5cc and over. The three studies 
showed a similar pattern of an initial sharp drop at one month.  All studies 
then showed a rise at 3 months and again at six months.  When 
amalgamated, there was no significant difference from baseline and at six, 
nine and 12 months.   There was a similar pattern for the five individual 
domains of the IIEF (erectile function, orgasmic function, sexual desire, 
intercourse satisfaction and overall satisfaction). Patients were not given 
specific penile rehabilitation but phosphodiesterase-5 inhibitors (PDE-5I) were 
used by 10% of men at baseline and 37% at 12 months.  The IIEF-15 and 
IIEF-15 EFD scores of men started on PDE-5I improved by 13 and 6 points.  
No patients required second line PDE-5I or surgical intervention for ED. 
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3.3.3 Focal photothermal ablation 
Focal photothermal or laser ablation was utilized in three phase one and one 
phase two clinical trials which all used the SHIM (IIEF-5) 26,29,33,38.  Eggener et 
al studied 27 patients who each had one to two lesions ablated using MRI 
guidance in a phase II trial which was the largest photothermal study identified 
in the search26.  The maximum diameter of lesions was 15mm and the 
estimated volume of each lesion was less than 2cm3.  Lesions were ablated 
with 5mm margins except when adjacent to the cavernosal nerves or the 
urethra. The small (11.6%) fall from baseline of 21.5 points recorded at one 
and three months was statistically significant from baseline but the difference 
at 12 months was not.   Oto et al followed nine men treated with MRI-guided 
focal laser ablation38.  Their lesions varied between four and 12 mm.  The 
mean baseline IIEF-5 of 19.0 changed very little over six months though the 
authors mention that one patient’s IIEF-5 fell by 12 points.  None of the 
photothermal ablation papers reported erectile aid and PDE5-I use. 
 
3.3.4 Focal vascular targeted photodynamic therapy (VTP) 
The search identified three papers which were phase two clinical trials23,24,32. 
Azzouzi et al pooled results of three clinical trials (PCM 201, PCM 202 and 
PCM 203) including the EF results published by Moore et al, also identified in 
the search23,32.  The amalgamated 117 patients, which included patients 
treated with dose escalation, had mean IIEF-15 EFD of 19.4 at baseline.  This 
fell to 12.9 at one month, then rose to 15.1 at three months and 15.3 at six 
months.  The small falls from baseline were not statistically significant.  
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3.3.5 Focal irreversible electroporation 
The search identified two prospective development studies which ablated LPC 
lesions with IRE 9,11. The 19 men in Valerio et al’s study only had disease in 
the anterior prostate gland, which varied in volume between 0.4 and 1.3cm3.  
IIEF-15 was reported on a graph in the appendix without numerical values.  
The Initial IIEF-15 of approximately 47 fell to approximately 35 after one week 
although the difference does not appear significant.  The IIEF-15 then 
appears to be similar to baseline at three, six, nine and 12 months following 
treatment.  Murray et al followed 25 men for over six months and reported the 
prostate cancer quality of life survey results at baseline (18.6), six months 
(16.2) and one year (21.1)9.  It is not stated whether the changes were 
statistically significant but the changes were clearly very small.  PDE5-I were 
used by two patients at baseline and two at 12 months follow up.  The volume 





3.4 Comparative studies 
Liu et al, Li et al and Barret et al compared different ablative treatments in the 
same study though none of the studies were randomized24,28,30.  
 
Liu et al prospectively compared WG cryoablation with WG HIFU30.   The 
cryotherapy group had larger mean prostate volumes than the HIFU group 
(36.71ml vs 21.97ml; p=0.00), higher presenting PSA (28.8ng/ml vs 
17.0ng/ml; p=0.055) and a higher proportion of over T2b disease (30.7% vs 
22.5%; p=0.059).  Both groups initially had good EF.  There was a significant 
fall in IIEF-5 score in both groups at 6 months.  There was minimal 
improvement from the initial fall up to 24 months for both modalities (table 1).  
The fall from baseline was statistically greater for WG cryotherapy than HIFU 
at all time points. 
 
Li et al compared men undergoing WG HIFU and focal cryotherapy: The 
authors reported penile length, testosterone levels, penile Doppler US peak 
systolic and end diastolic velocities, resistive index, testosterone levels and 
IIEF-15 EFD scores at baseline to 36 months (table 2)28.  The groups were 
not randomized but appear to have similar median age, presenting PSA, 
clinical stage and baseline IIEF15 EFD score.   IIEF-15 EFD score fell 
significantly for both modalities from 27.8 and 27.3 out of 30 at baseline for 
focal cryotherapy and WG HIFU to 9.8 and 15.5 at six months.  IIEF-15 EFD 
for patients who underwent focal cryotherapy remained lower at all time points 
to 36 months.  Scores improved at all time points from six months and there 
was no statistical difference from baseline at 24 months for WG HIFU and at 
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36 months for focal cryotherapy.  The groups had similar peak systolic 
velocities (PSV) at baseline, but the WG HIFU patients had better PSV at all 
other time points.  There were no differences in flaccid and erectile penile 
length or circumference.  All patients underwent penile rehabilitation. 
 
Barret et al compared focal HIFU, focal cryotherapy, focal VTP and focal 
brachytherapy:  The baseline IIEF–5 score was 19, 23 and 20 for cryotherapy, 
VTP and HIFU respectively.  The IIEF–5 scores fell by 5, 10, and 6 points to 






Deterioration in sexual health after any prostate cancer treatment is 
challenging to evaluate as it may result from erectile, ejaculatory or orgasmic 
dysfunction, decreased libido or psychological and relationship changes that 
occur after therapy.  Return to baseline function measured via validated EF 
outcomes was chosen as an objective outcome that is meaningful to patients 
and is surprisingly under reported in the literature.  Furthermore, it provides a 
more meaningful index when comparing treatment modalities for LPC. 
 
The search for this systematic review found that non-validated definitions of 
EF were used in 29 studies.  These included ‘erections good enough for 
penetration’, ‘erections good enough for satisfactory intercourse’ and no 
requirements for PDE-5I.  There were 10 papers identified which provided no 
definition at all.  The multiple different methods of reporting ED after ablative 
therapy meant meta-analysis was not possible.  In particular, very few studies 
report on return to baseline function.  
 
Nevertheless, it appears that focal therapy in general has a less detrimental 
effect on EF than WG therapies.  Focal PT, VTP and IRE appeared to cause 
very little change from baseline though the men in these studies tended to 
have low volume lesions.  The lack of randomized studies means inter-
modality comparison is difficult though from Li et al’s and Liu et al’s non-
randomized comparative studies, it would appear that WG HIFU is associated 
better EF than both focal and WG cryotherapy28,30.   
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ED after HIFU is likely to result from heat dissemination to the surrounding 
cavernosal nerves and accessory or aberrant pudendal arteries found in up to 
75% of men28,39. The cooling effect from cryotherapy extends 5mm from the 
ice ball and it is recommended to give the cancer focus a 10mm margin7.   It 
is therefore more difficult to achieve precise ablation than with HIFU and 
cryotherapy is hence more likely to cause extensive injury to the NVB7,30.  
 
Some of the studies incorporated penile rehabilitation, which also makes 
comparison of results more difficult. Regular use of PDE-5I has been shown 
to improve PSV and may enhance nerve regeneration after ablation40. The 
role and method of penile rehabilitation after RP remains controversial41-44.  
This study did not identify any randomized studies comparing penile 
rehabilitation techniques after ablative therapies.  The men in Li et al’s study 
all underwent PDE-5I and pump penile rehabilitation after WG HIFU 
recovered baseline EF by 24 months28. The men in Liu et al’s study did not 
receive penile rehabilitation and did not recover their baseline IIEF-5 by 24 
months30.  Despite these findings, there was no robust enough evidence to 
enable the authors to draw conclusions regarding the effectiveness of penile 
rehabilitation after ablative therapy and should be the focus of further studies. 
 
This systematic review is limited by heterogenous definitions of ED and a lack 
of randomized data.  The authors would strongly urge that the design of future 
trials of ablative therapies utilize objective, validated outcome measures such 
as the IIEF-5 or EPIC-26 which is within the international consortium for 
health outcomes measurement dataset at three monthly intervals up to at 
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least one year, with return to baseline function as the primary endpoint.  This 
will allow patients to make more informed decisions regarding their preferred 
treatment of LPC when they weigh up the oncological success and functional 






Legend 1: Figure 1 – Flow diagram of evidence acquisition in a 
systematic review on erectile dysfunction following whole gland and 
focal ablative therapies for localized prostate cancer 
 Publications identified 
from database search  
 n = 222 
• Pubmed (n = 214) 
• Scopus (n = 8) 
• Cochrane (n = 0) 
Excluded studies based on abstract evaluation 
(n = 163) 
• Duplicates (n = 8) 
• Non-English language (n= 16) 
• Animal or cellular studies (n = 5) 
• Review articles and commentaries  (n = 46) 
• Letters (n = 1) 
• Description of trial or technique (n = 4) 
• Survey (n = 1) 
• Fewer than 5 patients (n=1) 
• Less than 6 month follow up (n = 2) 
• Non-prostate cancer (n = 14) 
• Non-ablative therapy (n = 45) 
• Salvage therapy (n = 20) 
Selected articles for full 
text evaluation 
 n = 59 
Excluded studies based on full text evaluation (n 
= 42) 
• Salvage therapy identified on full text evaluation (n = 
2) 
• Endpoint not UCLAPCI, EPIC, IIEF – 15, IIEF – 5, SHIM  
or other validated questionnaire(n = 28) 
• IIEF given as range (n = 7) 
• Ablative therapy not specified whether WG or focal (n 
= 3) 
• No full text available (n = 2) 
Selected articles for 
systematic review 





Legend 2: Figure 2 – UCLAPCI sexual function and sexual bother 
scores, median total IIEF-5 and  IIEF-15 EFD scores for studies that 
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Legend 3: Figure 3 – Median total IIEF-5, IIEF-15 EFD and IIEF-15 scores for studies that reported erectile function 
outcomes following WG HIFU therapy[7,23,26,29,34] 
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Legend 5: Figure 5 - Median total IIEF-15 scores at baseline to 12 months for studies that reported erectile function 
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Legend 6: Table 1 – Liu et al IIEF–5 scores at baseline to 24 months30 
   
 WG Cryotherapy WG HIFU p 
Age [SD] (y) 68.8 [6.5] 68.1 [1.9] 0.33 
Prostate volume [SD] (ml) 36.7 [16.9] 22.0 [10.9] 0.000 
PSA [SD] (ng/ml) 26.8 [49.3] 17.0 [21.9] 0.055 
    
Gleason score:   0.082 
6 41 (36.0%) 36 (30.0%)  
7 38 (33.3%) 57 (47.5%)  
≥8 35 (30.7%) 27 (22.5%)  
T stage:   0.059 
<T2b 52 (45.6%) 73 (60.8%)  
T2b 16 (14.0%) 14 (11.7%)  
T2b 46 (40.4%) 33 (27.5%)  
    
IIEF-5 [SD]    
Baseline  22.96 [2.44] 22.10 [2.62] 0.112 
6 months 4.02 [5.95] 8.55 [8.41] 0.017 
12 months 3.61 [5.21] 9.67 [7.74] 0.004 
18 months  4.50 [5.96] 10.16 [8.11 0.001 
24 months 4.18 [5.89] 9.36 [6.33] 0.0028 
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Legend 7: Table 2– Li et al IIEF–15 EFD scores at baseline to 36 
months28 
    
 Focal Cryotherapy WG HIFU p 
Age [SD] (y) 59.2 [4.9] 57.5 [5.7] 0.36 
PSA [SD] (ng/ml) 8.2 [3.1] 7.5 [2.4] 0.88 
    
T stage:   0.69 
T1c 21 (44.7%) 24 (43.6%)  
T2a 24 (51.0% 26 (47.3%)  
T2b 2 (4.3%) 5 (9.1%  
    
IIEF-15 EFD [SD]    
Baseline 27.8 [2.1] 27.3 [2.5] 0.735 
6 months 9.8 [3.1] 15.5 [4.2] <0.001 
12 months 11.5 [3.6] 17.6 [4.1] 0.021 
18 months 13.9 [4.4] 18.4 [4.6] 0.016 
24 months 16.4 [4.9] 22.3 [5.3] 0.003 
36 months 22.7 [5.4] 26.2 [3.5] 0.042 
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modality Study n Age (y) 
Presenting 
PSA 










WG therapy:           
WG cryotherapy Liu et al, 2015 114 69.8 26.8 IIEF-5 22.96 24 0, 6, 12, 18 ,24 





Malcolm et al, 
2006 81 71 6.2 
UCLAPCI sexual 
function and 
bother 60 & 80 36 
0, 3, 6, 12, 18, 
24, 30, 36 




           
WG HIFU Shoji et al, 2010 326 68 12.7 IIEF-5 6.33 24 0, 6, 12, 24 NSC*** 
Not 
reported 
 Liu et al, 2015 120 68.1 17.0 IIEF-5 22.1 24 0, 6, 12, 18 ,24 




 Ahmed et al, 2009 94 64.1 8.3 IIEF-15 33.8 12 0, 1, 3, 6, 9, 12 6**** 
Not 
reported 




Chin et al, 2016 30 59 5.8 IIEF-15 EFD 13 12 0, 1, 3, 6, 12 3 
Not 
reported 
           
Focal 
cryotherapy Barret et al, 2013 50 66.5** 6.2 IIEF-5 19 12 0, 12 NSC*** 
Not 
reported 
 Li et al, 2010 47 59.2 8.2 IIEF-15 EFD 27.8 36 0, 6, 12, 18, 24 36 
100%*****
* 
           
Focal therapy:           
Focal HIFU Yap et al, 2015: 
         
 
ALL 118 63 6.8 IIEF-15 58 12 0, 1, 3, 6, 9, 12 6 43%* 
 
FOCAL 42 60 7.4 IIEF-15 64 12 0, 1, 3, 6, 9, 12 
  
 
HEMI 20 64 6.6 IIEF-15 54 12 0, 1, 3, 6, 9, 12 
  
 
LESION CONTROL 56 63 6.5 IIEF-15 58 12 0, 1, 3, 6, 9, 12 
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Barret et al, 2013 21 66.5** 6.0 IIEF-5 20 12 0, 12 NSC*** 
Not 
reported 
           
Photothermal 




Natarajan et al, 
2015 8 63 10.3 IIEF-5 19.5 6 0, 1, 3, 6 NSC*** 
Not 
reported 
 Oto et al, 2013 9 61 5.5 IIEF-5 19.0 6 0, 1, 3, 6 NSC***  
 Lindner et al, 2009 12 56.5 5.7 IIEF-5 22 6 0, 1, 3, 6 NSC*** 
Not 
reported 
           
VTP Azzouzi et al, 2015 117 62.2 5.6 IIEF-15 EFD 19.4 6 0, 1, 3, 6 NSC*** 
Not 
reported 
 Barret et al, 2013 23 66.5** 5.7 IIEF-5 23 12 0, 12 NSC*** 
Not 
reported 
           




Katie S. Muuray et 
al, 2016 25 63.1 4.3 
Prostate quality of 
life survey 18.6 12 0, 6, 12 





no de novo 
use 
* 38% of started taking PDE-5I after ablative therapy 
      ** This is the median age for all patients, the median ages of the individual groups were not reported 
  *** No significant change from baseline score at any time point 
     **** A significant number of patients were not followed up from baseline 
    ***** The EF score did not return to baseline within the follow up period after an initial significant fall  
  ****** All patients were also encouraged to use a vacuum pump 
     ******* Results extrapolated from graph      
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Legend 9: Table 4 – Papers identified by review with bias assessment 
 
 






Time taken for EF to return to 








24 WG HIFU IIEF-15 No 12 
No control group 
Low rate of follow up 




41 Focal HIFU IIEF-15 Yes 12 
No control group 






114 Focal VTP IIEF-EF 
No 
(follow up scores less than 
baseline) 
6 
None of the studies within the 
amalgamation had control groups 
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HIFU (21) & 
focal VTP 
(23) 
IIEF-5 No 12 
Treatment groups not randomised 
 
Outcome of interest only reported at 
baseline and 12 months 
Chin et al, 201610 
Prospective 
cohort (phase I 
trial 
30 WG HIFU IIEF-15 EFD No 12 
No control group 
Eggener et al, 
201611 
Phase II trial 27 
Focal 
photothermal 
SHIM (IIEF-5) Yes 12 
No control group 





(55) & Focal 
Cryo (47) 
IIEF –EF No 36 
Groups not randomised, all patients 
encouraged to use a vacuum pump 
Lindner et al, 
200914 
Prospective 





IIEF -5 (graph 
only) 
No 6 
No control group, small study 









(follow up scores less than 
baseline) 
24 
Treatment groups not randomised 
and WG cryotherapy group had 
higher presenting PSA and larger 
prostate volumes 









(follow up scores less than 
baseline) 
36 
No control group 
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Moore et al 
201517 
Prospective 
cohort (phase II 
trial) 
34 Focal VTP IIEF-5 
No 
(no statistical difference between 
baseline and any time point in 
study) 
6 
No control group 
Katie S. Murray 









quality of life 
survery 
No 12 
No control group 
Natarajan et al, 
201518 
Prospective 







(no statistical difference between 
baseline and any time point in 
study) 
6 
Small study, no control group 
Oto et al, 201338 
Prospective 








(no statistical difference between 
baseline and any time point in 
study) 
6 
Small study, no control group 
Shoji et al, 201019 
Prospective 
cohort 
326 WG HIFU IIEF-5 
No 
(no statistical difference between 
baseline and any time point in 
study) 
24 
No control group 
Valerio et al 
201711 
Prospective 










No control group 
Yap et al, 201620 
Pooled analysis 
of 3 prospective 
studies 
118 Focal HIFU 
IIEF–15 & IIEF 
– EF 
Yes 12 
None of the studies within the 
amalgamation had control groups 
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Appendix A – Search terms for PubMed 
(("focal therapy"[All Fields] OR ("laser therapy"[MeSH Terms] OR ("laser"[All 
Fields] AND "therapy"[All Fields]) OR "laser therapy"[All Fields] OR ("laser"[All 
Fields] AND "ablation"[All Fields]) OR "laser ablation"[All Fields]) OR ("high-
intensity focused ultrasound ablation"[MeSH Terms] OR ("high-intensity"[All 
Fields] AND "focused"[All Fields] AND "ultrasound"[All Fields] AND 
"ablation"[All Fields]) OR "high-intensity focused ultrasound ablation"[All 
Fields] OR "hifu"[All Fields]) OR ("cryotherapy"[MeSH Terms] OR 
"cryotherapy"[All Fields]) OR ABLATION[All Fields]) AND ("prostatic 
neoplasms"[MeSH Terms] OR ("prostatic"[All Fields] AND "neoplasms"[All 
Fields]) OR "prostatic neoplasms"[All Fields] OR ("prostate"[All Fields] AND 
"cancer"[All Fields]) OR "prostate cancer"[All Fields]) AND ((("penile 
erection"[MeSH Terms] OR ("penile"[All Fields] AND "erection"[All Fields]) OR 
"penile erection"[All Fields] OR "erectile"[All Fields]) AND 
("physiology"[Subheading] OR "physiology"[All Fields] OR "function"[All 
Fields] OR "physiology"[MeSH Terms] OR "function"[All Fields])) OR ("erectile 
dysfunction"[MeSH Terms] OR ("erectile"[All Fields] AND "dysfunction"[All 
Fields]) OR "erectile dysfunction"[All Fields]) OR SEXUAL FUNCTION[All 
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